Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity

Area of Science:

• Immunology
• Gerontology
• Psychiatry

Background:

• Aging impairs immune function, increasing susceptibility to infections and reducing vaccine efficacy in the elderly.
• Major depressive disorder (MDD) is associated with accelerated biological aging.
• This overlap suggests potential shared vulnerabilities in immune responses between elderly and depressed individuals.

Purpose of the Study:

• To conduct an umbrella review of existing literature on the immune response in depression, particularly in the context of the SARS-CoV-2 pandemic.
• To assess if depression poses risks comparable to advanced age regarding infectious disease and vaccination.
• To inform public health strategies concerning vulnerable populations during pandemics.

Main Methods:

• Umbrella review of scientific literature.
• Analysis of studies examining immune responses in elderly individuals.
• Synthesis of research on the immunological effects of major depressive disorder.
• Contextualization within the COVID-19 pandemic and SARS-CoV-2 infection.

Main Results:

• Evidence suggests depression is a risk factor for negative outcomes following COVID-19 infection.
• Data indicate that individuals with MDD exhibit reduced immunogenicity to COVID-19 vaccines.
• Depression appears to confer immune-related risks similar to those observed in the elderly population.

Conclusions:

• Major depressive disorder (MDD) should be recognized as a condition conferring vulnerability, similar to advanced age.
• Individuals with MDD represent a high-risk group that warrants priority for vaccination.
• Public health policies should include psychiatric disorders, such as MDD, among priority groups for vaccination during pandemics like COVID-19.